PROCEPT BioRobotics Corporation

Background

Company Name	PROCEPT BioRobotics Corporation
Stock Symbol	PRCT

Submit Your Information

If you suffered a loss on your PROCEPT BioRobotics Corporation investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 01, 1970?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On February 25, 2026, Procept reported fourth quarter and full year 2025 results, disclosing a larger-than-expected adjusted EBITDA loss and cutting its full-year 2026 revenue guidance to a range of $390 million to $410 million (down from its prior range of $410 million to $430 million). The Company attributed lower U.S. consumable revenue in part to eliminating its historical practice of providing discounts on bulk purchases in order to better align handpiece sales with procedure volumes.

On this news, Procept’s stock price fell $4.21 per share, or 15.12%, to close at $23.63 per share on February 26, 2026, thereby injuring investors.

Submit Your Information